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Abstract
Background: Although polymorphisms of PRNP, the gene encoding prion protein, are known as a determinant
affecting prion disease susceptibility, other genes also influence prion incubation time. This finding offers the
opportunity to identify other genetic or environmental factor (s) modulating susceptibility to prion disease. Ribosomal
protein SA (RPSA), also called 37 kDa laminin receptor precursor (LRP)/67 kDa laminin receptor (LR), acts as a receptor
for laminin, viruses and prion proteins. The binding/internalization of prion protein is dependent for LRP/LR.
Methods: To identify other susceptibility genes involved in prion disease, we performed genetic analysis of RPSA.
For this case-control study, we included 180 sporadic Creutzfeldt-Jakob disease (CJD) patients and 189 healthy
Koreans. We investigated genotype and allele frequencies of polymorphism on RPSA by direct sequencing or
restriction fragment length polymorphism (RFLP) analysis.
Results: We observed four single nucleotide polymorphisms (SNPs), including -8T>C (rs1803893) in the 5’-
untranslated region (UTR) of exon 2, 134-32C>T (rs3772138) in the intron, 519G>A (rs2269350) in the intron and
793+58C>T (rs2723) in the intron on the RPSA. The 519G>A (at codon 173) is located in the direct PrP binding site.
The genotypes and allele frequencies of the RPSA polymorphisms showed no significant differences between the
controls and sporadic CJD patients.
Conclusion: These results suggest that these RPSA polymorphisms have no direct influence on the susceptibility to
sporadic CJD. This was the first genetic association study of the polymorphisms of RPSA gene with sporadic CJD.
Background
Human prion diseases are fatal transmissible neurode-
generative disorders with accumulation of an abnormal
infectious isoform (PrP
Sc) in central nervous system and
spleen. Approximately 85% of Creutzfeldt-Jakob disease
(CJD) is sporadic CJD that differs from generically
linked variant CJD in its relatively late age incidence
and short duration of illness [1,2]. It is known that the
conformational conversion of naturally expressed cellu-
lar prion protein (PrP
C)t oP r P
Sc is the key event in the
pathogenesis of prion disease.
It is known that homozygous codon 129 of human
prion protein gene (PRNP) increases the risk of CJD.
Although about 40% of the British and about 95% of the
Korean have this genotype, the incidences of sporadic
CJD are similar [3-5]. This epidemiological data suggests
that allelic frequencies of PRNP codon 129 are unlikely
to be the sole genetic factor for sporadic CJD incidence
[3]. Inbred mouse lines encoding the same PRNP geno-
type differed significantly in incubation time [6,7]. In
addition, new quantitative trait loci (QTL) that affect
prion disease incubation time have been detected [7-9].
These results make it possible to study other candidate
loci and factors that play a role in the onset time of prion
disease.
The 37 kDa laminin receptor precursor (LRP)/67 kDa
laminin receptor (LR) is a multifunctional protein which
* Correspondence: bhjeong@hallym.ac.kr; yskim@hallym.ac.kr
1Ilsong Institute of Life Science, Hallym University, 1605-4 Gwanyang-dong
Dongan-gu, Anyang, Gyeonggi-Do 431-060, Republic of Korea
Full list of author information is available at the end of the article
Yun et al. BMC Medical Genetics 2011, 12:108
http://www.biomedcentral.com/1471-2350/12/108
© 2011 Yun et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.acts as a receptor for laminin and is involved in organi-
zation of basement membrane [10]. LRP forms its
mature LR by unknown mechanism involving post-
translational fatty acid acylation [11,12]. LRP exists on
the cell surface and LR is embedded in cell membrane
[11]. The open reading frame (ORF) of the human LRP/
LR gene, also called ribosomal protein SA (RPSA), is
888 bp in length, codes a protein of 295 amino acids
and is found on chromosome 3p22.2. The amino acid
sequence of RPSA shares high homology in mammals
[10]. LRP/LR also acts as a receptor for many compo-
nents; carbohydrates, elastin, green tea catching epigallo-
catechin-3-gallate (EGCG), various viruses, bacteria and
prion protein [11,12]. LRP/LR can be a factor in patho-
logical processes. In cancer, LRP/LR is upregulated and
its overexpression is associated with tumor cell metasta-
sis and attack [11,12]. In prion disease, LRP/LR acts as a
receptor for PrP
Sc as well as a receptor or co-receptor
for PrP
c [11-15]. PrP
c is co-localized with LRP/LR on
the surface of mammalian cells [13]. Enhanced LRP/LR
level was only found in systems converting PrP
c to PrP
Sc
and in organs accumulating PrP
Sc such as brain, spleen
and pancreas in scrapie-infected mice and hamsters [15].
Bovine prion protein (PrP
BSE) after oral infection is inter-
nalized by human enterocytes via a specific LRP/LR-
dependent process [16]. LRP/LR is essential for the
propagation and accumulation of PrP
Sc in scrapie-
infected cells, and its expression is related to the degree
of PrP
Sc propagation [17,18]. Therefore, it is possible that
PrP-LRP-LR interaction is related to pathogenesis of
prion disease. LRP/LR also has potential as an alternative
therapeutic strategy that aims at LRP interactions [19,20].
Recent studies showed that inactivation of LRP/LR inter-
feres with either PrP
Sc propagation or PrP
Sc accumula-
tion, leading to a prolonged pre-clinical phase and
incubation times in scrapie-infected mice [21,22]. Cate-
chin EGCG, a component in green tea, represents anti-
allergic, anti-tumor and anti-obesity actions via binding
to LRP/LR [23-25]. EGCG treatment interferes with the
formation of PrP
Sc in scrapie-infected cells and with the
stress-protective effect of PrP
c in uninfected cells [26].
Although PrP-LRP-LR interaction is important for
prion disease, a relationship between RPSA polymorph-
ism and prion disease has not been reported. Therefore,
we investigated polymorphisms of human RPSA,a n d
studied whether these polymorphisms are related to sus-
ceptibility to sporadic CJD.
Methods
Subjects
This study included 180 sporadic CJD patients (93 male
and 87 female; mean age at disease onset 61.4 ± 12.0)
and 189 healthy controls (89 male and 100 female;
mean age at blood collection 71.7 ± 8.9) who were all
unrelated and from an ethnically homogenous Korean
population (Table 1). Blood samples were collected from
May 1996 to April 2006.
The clinical criteria for sporadic CJD patients were
established according to the WHO diagnostic criteria for
definite or probable CJD [27]. In brief, definite CJDs were
neuropathologically confirmed and/or immunochemically
detected by presence of PrP
Sc in the brain. Probable CJDs
were diagnosed by presence of progressive dementia, a
typical electroencephalography (EEG), and/or a positive
14-3-3 protein in CSF and a clinical duration leading to
death in <2 years and at least two of the following: myo-
clonus, visual or cerebellar disturbance, pyramidal, extra-
pyramidal dysfunction, akinetic mutism. Patients with
mutation in the PRNP were excluded from this study. 12
definite sporadic CJD and 168 probable sporadic CJD
cases were enrolled in our study.
All healthy control subjects participated voluntarily
during routine checkups at the Chuncheon Sacred Heart
Hospital and Hallym University Sacred Heart Hospital.
The purpose of the study was carefully explained to all
study participants or their representatives and their
informed consents were obtained. The study complied
with the Guidelines for Genome/Genetic Research issued
by the Korean government and was approved by the
Ethical Committee of Hallym University Sacred Heart
Hospital, Anyang, Korea.
Genetic analysis
Whole blood samples were drawn into ethylenediaminete-
traacetate (EDTA)-treated tubes and were kept frozen at
-70°C until analysis. Genomic DNA was extracted from
whole blood using the QIAamp
® DNA blood Mini Kit
(QIAGEN, Valencia, CA, USA) according to the manufac-
turer’s instruction. For the screening polymorphisms in
the LRP/LR, polymerase chain reaction (PCR) was per-
formed with forward primer and reverse primer (Table 2).
A5 0μL reaction mixture containing 10 μLo fg e n o m i c
DNA, 1 μL each of forward and reverse primers, 4 μLo f
2.5 mM dNTP mixture, 5 μL of 10X Taq DNA polymerase
buffer (Promega, Madison, WI., USA), 0.5 μL of 2.5units
Taq DNA polymerase (Promega, Madison, WI., USA) and
23.5 μL of sterile deionized water was placed in PTC-200
Peltier Thermal Cycler (MJ Research, Reno, NV, USA).
PCR reactions were thermally cycled with an initial dena-
turation at 90°C for 3 minutes, followed by 35 cycles of
95°C for 30 seconds, 57°C for 30 seconds and 72°C for
1.5 minutes and then a final extension at 72°C for 4 min-
utes. Each PCR product was run on a 1% agarose gel
stained with ethidium bromide (EtBr), and then was puri-
fied by QIAquick
® Gel Extraction Kit (QIAGEN, Valencia,
CA., USA). The PCR products were directly sequenced
with an ABI 3730 Capillary Electrophoresis Sequencer
(Applied Biosystems, Foster City, CA, USA).
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Page 2 of 7Alleles of RPSA 2, RPSA 4a n dRPSA 5 were deter-
mined by PCR restriction fragment length polymorphism
(RFLP). Restriction sites were searched using Webcutter
2.0 http://rna.lundberg.gu.se/cutter2. Restriction digests
(enzymes supplied by Fermentus) were performed in a
20 μL reaction mixture containing 10 μL of PCR reaction
mixture, 2 μL of 10× buffer B, 0.5 μLo fT a s Ι and 7.5 μL
of sterile deionized water was digested at 65°C for
4 hours. Digested PCR products were electrophoresed on
a 2% agarose gel and visualized with EtBr staining under
UV light.
Statistical analysis
Statistical data were carried out using Statistical Analysis
Software (SAS), version 8.2 (SAS Institute Inc., Cary, NC.,
USA). The c
2 test was used to assess differences between
categorical variables. Difference between the two groups
regarding genotype frequencies were determined by Fish-
er’s exact test, and comparisons of allele frequencies were
assessed by c
2-test. Student’s t-test was used to analyze
differences between the normal population and sporadic
CJD patients by age. Hardy-Weinberg Equilibrium test
and haplotype analysis were performed by use of the
SNPAnalyzer 1.2A http://snp.istech21.com/snpanalyzer/
1.2A/. Linkage disequilibrium (LD) between paired poly-
morphisms was tested.
Results
To identify an association between RPSA polymorph-
isms and sporadic CJD, we screened nucleotide
variations in RPSA using direct gene sequence or RFLP
analysis. We observed four single nucleotide polymorph-
isms (SNPs), including -8T>C (rs1803893) in the 5’-
untranslated region (UTR) of exon 2, 134-32C>T
(rs3772138) in the intron, 519G>A (rs2269350) in exon
5 and 793+58C>T (rs2723) in the intron. The genotype
frequencies of all SNPs followed Hardy-Weinberg equili-
brium except for RPSA 793+58C>T in controls (data not
shown).
We analyzed the extent of LD between the polymorph-
isms. Four SNPs identified in the RPSA were strongly
linked together with D’ values 0.94 - 1.00 (Table 3).
Because four RPSA polymorphisms are in strong LD, we
analyzed the genotype frequency of RPSA 5’-UTR -8T>C
using direct sequencing, whereas frequencies of other
genes were determined using RFLP analysis. As shown in
Table 4, there was no significant difference in the genotype
distribution of the RPSA polymorphisms between controls
and sporadic CJD groups. Allele frequencies of RPSA poly-
morphisms also showed no differences between these two
groups. In addition, the genetic variations of these poly-
morphisms were equally frequent by gender (data not
shown).
As shown in Table 5, five different haplotypes exist in
the RPSA polymorphisms: TCGT, CTAC, TCGC, CCGC
and CTGT. Among the five haplotypes, the haplotype
TCGT was observed more frequently (67% for controls;
69% for sporadic CJD patients); the second major haplo-
type was CTAC (18% for controls; 19% for sporadic CJD
patients). The haplotype CTGT was less frequently
Table 1 General characteristics of healthy controls and sporadic CJD patients
healthy controls
(n = 189)
Sporadic CJD patients
(n = 180)
P-value
Gender
Male, n (%) 89 (47.1%) 93 (51. 7%) 0.379
Female, n (%) 100 (52.9%) 87 (48.3%)
Mean age at disease onset (yrs) - 61.4 ± 12.0 <0.01
Mean age at blood collection (yrs) 71.7 ± 8.9 -
Data are mean ± S.D. or percentage
Table 2 PCR primers used to screen the RPSA
Primer identity Primer sequences Nucleotide position Product size
RPSA 1 A: GAT GTG CGC TGT TCC GTA AT
B: TCA TGT TCA TGA CCC AAC CC
1026-1601 576 bp
RPSA 2 A: GGA AAG AGT GGC AGA AAG CC
B: TGC TGG GAT TAC AGG CGT AG
1866-2431 566 bp
RPSA 3 A: CCA GTG CCC AGA AGT GCT TA
B: TTC ATC GGC CAG TCA GTA GC
4252-4681 430 bp
RPSA 4 A: GCT TGC TGT TTG GGT TTG AC
B: TTC CTT ACC CCA CTC CCA AC
5171-5799 629 bp
RPSA 5 A: AAG CAA AAC TTG TCA GTC CCT G
B: CAA CCA TTT TTC CAT GCT GC
5421-5990 570 bp
’A’ indicates the forward primer, and ‘B’ indicates the reverse primer.
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for both controls and sporadic CJD patients). Analysis of
the haplotype frequencies of RPSA polymorphisms
showed no significance between controls and sporadic
CJD patients.
In order to identify whether the RPSA polymorphism
affects susceptibility to sporadic CJD, we tested for LD
with PRNP codon 129 polymorphism. Because four
RPSA polymorphisms have strong LD, we only tested
RPSA 1 polymorphism. The RPSA 5’-UTR - 8T>C poly-
morphism is in low LD with both PRNP codon 129
polymorphism and 219 polymorphism (D’ =0 . 4 9 7a n d
D’ = 0.110, respectively).
To identify the combined effects of RPSA and PRNP on
susceptibility to prion disease, RPSA 5’-UTR -8T>C gen-
o t y p ed a t aw a ss t r a t i f i e dw i t hPRNP codon 129 and with
codon 219 genotypes (Table 6). We found no significant
differences in the genotype and allele frequencies of
RPSA 5’-UTR -8T>C polymorphism according to the
PRNP codon 129 status. Similar results were seen when
stratified with PRNP codon 219.
Discussion
In order to find association of RPSA with sporadic CJD, we
screened sequence of the RPSA in all available samples of
sporadic CJD patients from Korean populations and inves-
tigated SNPs in the LRP/LR gene. In this study, we identi-
fied four polymorphisms including 519G>A (at codon
173) in the coding region and three SNPs located in 5’-
UTR and intron on the RPSA. By two-hybrid system in
the yeast and cell-binding assay, two PrP-LRP-LR interac-
tion domains on PRNP were identified: a direct binding
domain amino acids 144-179, termed PrPLRPbd1 and an
indirect heparin sulfate proteoglycan (HSPG)-dependent
LRP binding domain amino acids 53-93, termed
PrPLRPbd2 [28]. On RPSA, the direct PrP binding site is
amino acids 161-180 and the heparin sulfate-dependent
PrP-binding site is amino acids 205-229 [29]. The RPSA
polymorphism at codon 173 is a synonymous SNP, which
encodes leucine, and does not lead to substitution of
amino acid. Nevertheless, it remains of interest, because
the polymorphism at codon 173 is located in the direct
PrP binding domain. Similar to our study, ovine RPSA
polymorphisms in the regions related to PrP-LRP-LR
interaction did not lead to a change in amino acid
sequence [30]. Although the effects of this SNP on LRP/
LR biology or prion biology are unknown, it is possible
that the differences in combinations of amino acids may
modify its specificity with other proteins affecting PrP-
LRP-LR interaction, strengthening or weakening the spe-
cies barrier [30]. The RPSA amino acid sequences asso-
ciated with resistance barrier to scrapie infection have
been identified at positions 241, 272 and 291 in goat [31],
and at positions 241, 271 and 290 in sheep [30]. SNPs in
UTR are known to have an effect on the expression or sta-
bility of genes. It is possible that the 5’-UTR -8T>C poly-
morphism may be responsible for genetic susceptibility to
sporadic CJD.
In addition to differences in LRP/LR amino acid
sequence, which affects the interaction with PrP
Sc, differ-
ences in the production/expression of LRP/LR bioavail-
ability at the cell surface and particular conformations
might be regional leading to cellular differences in bind-
ing/accumulation of prion proteins; the result of these
differences could lead to variable response to scrapie
infection [30,32]. LRP is relatively abundant in develop-
ing brain tissue, and its expression is limited to a few
Table 3 D’ Values for Linkage Disequilibrium (LD)
between RPSA polymorphisms
5’-UTR -8T>C 134-32C>T 519G>A 793+58C>T
5’-UTR -8T>C - 1.00 1.00 0.94
134-32C>T - - 1.00 0.96
519G>A - - - 1.00
793+58C>T - - - -
Table 4 Genotype and allele frequencies of RPSA polymorphisms in controls and sporadic CJD patients
5’-UTR -8T>C 134-32C>T 519G>A 793+58C>T
Controls
(n = 189)
Sporadic CJDs
(n = 180)
Controls
(n = 50)
Sporadic CJDs
(n = 50)
Controls
(n = 50)
Sporadic CJDs
(n = 50)
Controls
(n = 50)
Sporadic CJDs
(n = 50)
Genotype
1/1 91 (48.2%) 87 (48.3%) 33 (66.0%) 33 (66.0%) 34 (68.0%) 33 (66.0%) 28 (56.0%) 24 (48.0%)
1/2 77 (40.7%) 78 (43.3%) 15 (30.0%) 15 (30.0%) 14 (28.0%) 15 (30.0%) 12 (24.0%) 22 (44.0%)
2/2 21 (11.1%) 15 (8.4%) 2 (4.0%) 2 (4.0%) 2 (4.0%) 2 (4.0%) 10 (20.0%) 4 (8.0%)
P-value 0.646 1.000 1.000 0.058
Allele
1 279 (0.70) 252 (0.70) 81 (0.81) 81 (0.81) 82 (0.82) 81 (0.81) 68 (0.68) 70 (0.70)
2 119 (0.30) 108 (0.30) 19 (0.19) 19 (0.19) 18 (0.18) 19 (0.19) 32 (0.32) 30 (0.30)
P-value 0.976 1.000 0.856 0.760
For columns ‘1’ refers to the more common genotype or allele and ‘2’ to the less common genotype or allele of each polymorphism.
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abnormal prion accumulation, and these cells rapidly
degenerate during the early stages of CJD [32,33]. LR is
expressed in most adult neurons, and a subset of glial
cells and astrocytes, which can accumulate PrP
Sc in scra-
pie-infected hamsters [32]. PrP
C-LRP-LR interaction,
related to prion protein binding/accumulation, may take
place at the cell soma and apical dendrites [32]. LRP is
localized in the cytoplasm and in the nucleus, and LR can
be present as a laminin-binding protein on the cell sur-
face or in a free form in the extracellular matrix [11,30].
As shown in Table 4, although we found no significant
difference in the genotype and allele frequencies of the
RPSA polymorphisms between controls and sporadic CJD
groups, RPSA 793+58C>T showed a tendency to lower
frequency of heterozygotes in sporadic CJD patients than
those of controls (P = 0.058). Since the number of RPSA
793+58C>T was much smaller (n = 50 for controls, n = 50
for sporadic CJD patients), further study on whether this
result relates to our small sample sizes is required. In our
study, the genotype and allele frequencies of RPSA poly-
morphisms were not influenced by gender. Lloyd et al. [7]
and Stephenson et al. [8] reported that prion disease incu-
bation time is not affected by sex. In contrast, the studies
of Moreno et al. [9] showed that the survival time of
female mice is shorter than those of male mice. The
source of this sex effect could be hormonal factors, body
size, fat composition, appetite and so on, acting at the end
of the survival time [9].
One major haplotype (TCGT) is present in both con-
trols and sporadic CJD patients with frequencies of 67-
69% (Table 5). The additional four haplotypes were not
significantly different in the two populations.
Some SNPs may act through LD with other mutations,
even if it may not have direct influence on sporadic CJD
susceptibility. From this point of view, we tested for LD
between RPSA polymorphisms and PRNP codon 129. We
found that RPSA polymorphisms had no effect on the sus-
ceptibility of 129MM individuals to sporadic CJD. To fully
elucidate the association of the RPSA polymorphisms with
sporadic CJD susceptibility, further studies are required
using various populations because different linkage pat-
terns can occur in different populations.
The PRNP associated resistance/susceptibility for
prion disease is likely to coexist with other genes modu-
lating its effect [30]. In previous studies, we found that
Table 6 Genotype and allele frequencies of RPSA 5-UTR -8T>C polymorphism according to the PRNP codon 129 or 219
status
PRNP 129 Healthy controls (n = 189) Sporadic CJD patients (n = 180) P-value
1 P-value
2
MM (n = 180) MV (n = 9) VV (n = 0) MM (n = 180) MV (n = 0) VV (n = 0)
Genotype frequency, n (%)
TT 84 (46.7) 7 (7.8) - 87 (48.3) - -
TC 75 (41.7) 2 (2.2) - 78 (43.3) - - 0.233 0.570
CC 21 (11.6) 0 (0) - 15 (8.3) - -
Allele frequency
T 0.68 0.89 - 0.70 - - 0.057 0.469
C 0.32 0.11 - 0.30 - -
PRNP 219 Healthy controls (n = 189) Sporadic CJD patients (n = 180) P-value
3 P-value
4
EE (n = 173) EK (n = 16) KK (n = 0) EE (n = 180) EK (n = 0) KK (n = 0)
Genotype frequency, n (%)
TT 86 (49.7) 5 (31.3) - 87 (48.3) - -
TC 68 (39.3) 9 (56.3) - 78 (43.3) - - 0.338 0.600
CC 19 (11.0) 2 (12.4) - 15 (8.3) - -
Allele frequency
T 0.69 0.59 - 0.70 - - 0.244 0.854
C 0.31 0.41 - 0.30 - -
1Difference in healthy controls with MM and healthy controls with MV.
2Difference in healthy controls with MM and sporadic CJD patients with MM.
3Difference in healthy controls with EE and healthy controls with EK.
4Difference in healthy controls with EE and sporadic CJD patients with EK.
Table 5 Haplotype frequency of RPSA polymorphisms in
controls and sporadic CJD patients
Haplotype Controls
(n = 50)
Sporadic CJDs
(n = 50)
P-value
TCGT 67.0% 68.9% -
CTAC 18.0% 19.0% 0.943
TCGC 9.0% 6.1% 0.574
CCGC 5.0% 4.9% 0.714
CTGT 1.0% 1.1% 0.983
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and 219 on PRNP in Koreans [4]. The PRNP poly-
morphism at codon 219 is unique to Asian populations,
and PRNP 219EK heterozygous genotype has a protec-
tive effect on sporadic CJD development [4]. In analysis
stratified by PRNP codon 129 or 219 status, we found
no significant difference in the genotype and allele fre-
quencies of RPSA 5’-UTR -8T>C polymorphism accord-
ing to the PRNP codon 129 or 219 status (Table 6).
These results are a function of the fact that all sporadic
CJD patients had only PRNP 129MM or 219EE
genotype.
Conclusions
Although RPSA alone is not a disease-modifying gene for
sporadic CJD in Koreans, these SNPs might have an effect
on the expression or susceptibility of RPSA gene and
PrP
C-LRP-LR interaction. In this case-control study, we
included only Korean populations; therefore this result
may not be generalized to other ethnicities. There are
comparatively few Koreans diagnosed with sporadic CJD;
this contributes to the limitation of the power analysis.
Nevertheless, this study is important in that it forms the
foundation of genetic association study on RPSA gene and
sporadic CJD. Further genetic studies on whether variants
in RPSA gene are associated with human prion disease
should examine various ethnicities and larger numbers.
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